Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Short Interest Update

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was the target of a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 97,300 shares, a decrease of 99.4% from the January 15th total of 15,930,000 shares. Based on an average daily volume of 1,530,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 1.7% of the shares of the stock are short sold.

Institutional Trading of Tonix Pharmaceuticals

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. Commonwealth Equity Services LLC bought a new stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 120,292 shares of the company’s stock, valued at approximately $40,000. Commonwealth Equity Services LLC owned about 6.43% of Tonix Pharmaceuticals as of its most recent filing with the SEC. Institutional investors own 82.26% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on shares of Tonix Pharmaceuticals in a research note on Monday. They set a “sell” rating on the stock.

Tonix Pharmaceuticals Trading Down 0.2 %

Shares of NASDAQ TNXP traded down $0.03 during midday trading on Wednesday, hitting $11.92. The stock had a trading volume of 454,178 shares, compared to its average volume of 1,545,993. The company’s 50-day simple moving average is $29.36 and its 200 day simple moving average is $25.32. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. The firm has a market cap of $22.28 million, a P/E ratio of 0.00 and a beta of 2.07. Tonix Pharmaceuticals has a fifty-two week low of $10.82 and a fifty-two week high of $1,248.00.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($23.00) earnings per share for the quarter, beating the consensus estimate of ($203.00) by $180.00. The company had revenue of $2.82 million during the quarter, compared to analysts’ expectations of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. Research analysts anticipate that Tonix Pharmaceuticals will post -1762.5 EPS for the current year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.